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above treatments and with the following endpoints: Sustained Virological Response 
(SVR), discontinuation of all medications (overall/due to Adverse Events (AE)), 
and incidence of anemia, rash (all grades) and pruritus-common adverse events 
of cHCV treatment. A Bayesian NMA was performed for all endpoints, assuming 
fixed study effects. Unpublished SMV studies meeting the inclusion criteria were 
obtained. Results: Three studies met the inclusion criteria: 2 phase III RCTs (SMV 
n= 183; TVR n= 189), and 1 SMV phase IIb RCT (n= 92). Baseline characteristics were 
generally comparable for all studies. SMV shows a higher odds ratio (OR) of achiev-
ing SVR versus TVR (OR 1.68 (0.66-4.26)). SMV shows a lower OR of discontinuation: 
overall 0.35 (0.12-1.00) and due to AEs 0.87 (0.23-3.34) versus TVR. SMV shows a lower 
OR of experiencing anemia 0.20 (0.07-0.56) and rash 0.42 (0.17-0.99) but a higher OR 
of experiencing pruritus 1.26 (0.46-3.47) versus TVR. The main limitation of this 
study is the small number of trials included in the analysis. ConClusions: In this 
indirect comparison, SMV, in combination with PegIFN/RBV, showed a favourable 
risk-benefit profile compared to TVR with PegIFN/RBV in Japanese treatment-naïve 
Hepatitis C infected patients.
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objeCtives: Two meta-analyses (York Health Economics Consortium [YHEC]; 
Cochrane) reported the beneficial effects of probiotics (live microorganisms which 
when administered in adequate amount confer a health benefit on the host). They 
demonstrated efficacy at reducing the duration and number of upper respiratory 
tract infections (URTI) and antibiotics use. The purchase of probiotics by consumers 
is likely to have positive externalities to the national health system and society. The 
aim of this analysis was to estimate the public health consequences of probiotics 
consumption, in France. Methods: A 1/1,000 virtual age and gender standardized 
population was generated using a Markov model (TreeAge 2009). URTI risk factors 
were age, active/passive smoking, living in the community. Influenza like illness (ILI) 
and flu daily incidence rates came from Sentinelles, a practitioner network aimed 
at identifying flu outbreak. Epidemiologic data were used to differentiate cold, ILI 
and flu. One-day cycles were used over the 2011-2012 flu season. Probiotics effects 
came from two meta-analyses. Outcomes included numbers of URTIs days and 
episodes, antibiotics courses and sick leave days avoided with probiotics. Results: 
According to YHEC data, probiotics reduced URTI episodes (average 7 days) by -0.77 
days [-1.5;-0.04]. Extrapolating these results to the French population, probiotics 
would save 2.85 million URTI-days, the number of antibiotic courses would drop 
from 1,004,000 to 674,000 (difference about -330,000) and the number of sick leave 
days avoided in adults would be 653,000. According to Cochrane data, probiotics 
would reduce the probability to have an URTI episode by 0.58 [0.36;0.92] and anti-
biotic prescription by 0.67 [0.45;0.98]. The probiotic impact would become larger in 
terms of URTI-days avoided (-7.1 million), antibiotic courses (-509,000) and workdays 
lost (-1.2 million). ConClusions: The probiotics public health impact on URTI is 
significant at a national level even though this analysis was restricted to the 1% of 
patients visiting a practitioner.
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objeCtives: To predict the future incidence of chronic hepatitis C in Russia and assess 
potential impact of the available antiviral therapies (pegylated interferon a-2a/a-2b 
or standard interferon a-2b combined with ribavirin) on long-term morbidity and 
mortality rates in the population of newly diagnosed Russian patients with chronic 
hepatitis C. Methods: Based on the national epidemiologic data and published natu-
ral history studies, the prognostic Markov model was developed. Depending on the 
results of antiviral therapy, patients’ flows over 25-year time frame were simulated. 
End points of interests included: the incidence of compensated and decompensated 
cirrhosis, hepatocellular carcinoma and cumulative time that patients will spend in 
each state, the number of patients, who will require liver transplantation, and HCV-
related mortality rates. Results: During years 2013-2017 about 276,000 new cases 
of chronic hepatitis C will be diagnosed in Russia. After 25 years since being diag-
nosed 130, 189 and 227 of 1,000 patients received pegylated interferon a-2a, pegylated 
interferon a-2b and standard interferon a-2b, respectively, will develop compensated 
cirrhosis. The cumulative time that patients will spend in compensated cirrhosis state 
will be 848, 1,218 and 1,482 patient-years, respectively. During the established time 
frame, there will be expected 25, 36 and 43 cases of hepatocellular carcinoma and 35, 
51 and 62 HCV-related deaths. 28, 40 and 49 patients, respectively, will require liver 
transplantation. ConClusions: The findings from the present study provide the 
opportunity to plan volumes of medical care that will be required to Russian patients 
with chronic hepatitis C during 25 years since disease was first diagnosed. The treat-
ment with pegylated interferon alfa-2a is considered the most preferable strategy 
due to considerably lower long-term morbidity and mortality rates as compared to 
pegylated interferon a-2b and standard interferon a-2b treatment.
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deaths due to DND. This study is limited by its ecological nature and more rigor-
ous epidemiologic research is needed to elucidate the association between LD 
and DND.
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objeCtives: High pill burden has been associated with poor adherence to HAART 
and adverse clinical outcomes. This study evaluated the impact of HAART as a 
single-tablet regimen (STR) and multiple-tablet regimen (MTR) on outcomes in 
HIV patients within the Veteran’s Affairs (VA) system. Methods: A retrospective, 
cohort study assessed patient VA dispensation data for HIV medications during 
the study enrollment period (7/1/2006 to 9/30/2011). Patients were assigned to the 
following cohorts: STR if they received a HAART regimen of a single tablet/day or 
MTR if they received a regimen of ≥ 2 tablets/day and no single tablet/day regimen 
during the enrollment period. Patients were followed from the index date (start 
of HAART regimen) until the earliest of treatment discontinuation, end of study 
period, or last date of health care-related activity (eg, VA benefits file or death). 
Hospitalization and adherence (medication possession ratio [MPR] ≥ 95%) were 
evaluated. Multivariate cohort differences in outcomes were controlled for using 
Cox-proportional hazard and logistic models; covariates were measured during 
a 6-month baseline period. Results: In all, 15,602 patients (STR, n= 6,191; MTR, 
n= 9,411) met study criteria; average age of the study sample was 52 years. Both 
cohorts had similar CD4 counts (mean [SD]: 432.2 [282.8] vs 419.3 [280.9]; P= 0.287) 
but significantly fewer patients receiving STR vs MTR had an undetectable viral load 
at baseline (42% vs 46%, P< 0.001). During follow-up, significantly more STR patients 
were adherent compared to MTR patients (75% vs 55.7%, P< 0.001). STR patients were 
also significantly less likely to experience hospitalization compared to MTR patients 
(26.8% vs 31.3%, P< 0.001). After controlling for baseline covariates, STR patients 
had twice the odds of being adherent (OR: 1.98, P< 0.001) and 31% lower hazard of 
experiencing hospitalization during follow-up (HR: 0.69, P< 0.001). ConClusions: 
Treatment with STR compared to MTR improves adherence rates and decreases 
hospitalizations in patients with HIV/AIDS.
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objeCtives: Sofosbuvir (SOF) is a nucleotide polymerase inhibitor with excellent 
clinical efficacy in combination with ribavirin (RBV) for 12 weeks for patients who 
are chronically infected with hepatitis C virus (HCV) genotype 2. A decision-analytic 
Markov model evaluated the health outcomes of SOF+RBV compared with current 
treatment options for patients who are previously untreated, had no response to 
prior interferon treatment, or are unable to take interferon. Methods: The analysis 
modeled 3 cohorts of chronic HCV genotype 2 patients with an average age of 50 
and 25% with cirrhosis at the start of treatment followed-up to 100 years of age from 
a US third-party payer perspective. SOF+RBV for 12 weeks was compared with 1) 
pegylated interferon (PegIFN)+RBV for 24 weeks in the treatment-naïve patients; 
2) PegIFN+RBV for 48 weeks in the treatment-experienced; and 3) no treatment in 
those unable to take interferon. Sustained virologic response (SVR) and adverse 
event rates were based on phase III clinical trials. Transition probability, utility, 
and cost estimates (in 2013 US dollars) were based on a literature review, public 
sources, and consensus by a panel of 4 hepatologists. Results: In the treatment-
naïve cohort, the SOF+RBV regimen resulted in an 83% decrease in the cases of 
liver disease complications including hepatocellular carcinoma, decompensated 
cirrhosis, liver transplant, and HCV-related death compared with PegIFN+RBV. The 
reduction of the listed liver disease sequelae was 59% in the treatment-experienced 
vs. PegIFN+RBV and 93% in the interferon-unable cohort vs. no treatment. The num-
ber needed to treat (NNT) with SOF+RBV rather than PegIFN+RBV to achieve one 
additional SVR was 6 in the treatment-naïve and 4 in the treatment-experienced 
cohorts. ConClusions: SOF+RBV was projected to yield better health outcomes 
in genotype 2 patients compared to PegIFN+RBV, largely driven by superior efficacy, 
and the potential to cure those who are unable to take interferon-based therapies.
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objeCtives: Simeprevir (SMV) is an oral, once-daily potent protease inhibitor for 
the treatment of chronic Hepatitis C genotype-1 infection (cHCV). In phase IIb/III 
RCTs conducted in Japan, SMV, in combination with peginterferon-α and ribavirin 
(PegIFN/RBV), demonstrated potent efficacy in cHCV genotype 1-infected patients 
relative to PegIFN/RBV and was generally safe and well-tolerated. Telaprevir (TVR) 
in combination with PegIFN/RBV is licensed for the treatment of cHCV in Japan. 
In the absence of head-to-head comparisons of TVR and SMV, we undertook a 
network meta-analysis (NMA) to examine the relative efficacy and safety of SMV 
and TVR in combination with PegIFN/RBV in a Japanese population. Methods: A 
systematic review identified RCTs in Japanese treatment-naive patients with the 
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Increasing treatment rate to 16% showed a decrease of 816/571 DCC and 260/182 HCC 
cases, 74/52 LTs and 655/458 LrDs. The overall reduction in ESLD cases was estimated 
to be -6.1%/-4.2% and -8.8%/-6.1% in both scenarios respectively. ConClusions: A 
1-year increase in treatment rate was predicted to reduce the burden of genotype-1 
CHC in 20 years in the UK. Different treatment rates across Europe imply unequal 
opportunities for patients to prevent CHC sequelae. Identifying CHC patients and 
offering antiviral therapy to maximise SVR could prevent substantial further severe 
liver disease and mortality.
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objeCtives: Approximately 1,000-1,200 people in the United States (US) develop 
meningococcal disease (MD) each year. MD is a life-threatening bacterial infection 
most common in infants (age < 1 year), adolescents, and persons living in close 
quarters. We estimated annual incidence and demographic characteristics of MD 
in the US pediatric population from 2000 to 2009. Methods: Data for pediatric (age 
≤ 20 years) MD-related hospitalizations (discharges with ICD-9-CM 036.xx) from the 
2000, 2003, 2006, and 2009 HCUP Kids’ Inpatient Databases (KID) were retrospec-
tively analyzed. Annual MD incidence per 100,000 pediatrics (adjusted to 2010 US 
population) was estimated using KID sampling weights and year-specific popula-
tion denominators from US census data. Results: Pediatric MD incidence steadily 
decreased from 1.9/100,000 in 2000 to 0.7/100,000 in 2009, a 63% decline. Incidence 
was highest, by far, in infants, which also decreased during 2000-2009 (7.6/100,000 
to 3.8/100,000, a 50% decline). Among children aged 1-4 years, incidence fell from 
2.7/100,000 to 0.8/100,000 during this period, a 70% decline. In children aged 5-10 
years, we observed a 75% decline (1.2/100,000 to 0.3/100,000); similar incidence and 
trends were seen for age groups 11-18 and 19-20 years. Pediatric MD cases were 
predominantly male, with male representation increasing from 55% to 61% of cases 
during 2000-2009. The racial composition of pediatric MD shifted somewhat dur-
ing this period, with representation declining among whites (from 56% to 45% of 
cases) and increasing among blacks (from 8% to 11% of cases). Geographic distribu-
tion remained fairly constant, with highest representation from the South (~30% of 
cases) and West (~30% of cases). ConClusions: Pediatric MD incidence declined 
during the 2000’s, possibly due to the introduction of the meningococcal conjugate 
vaccine in 2005. However, MD incidence remained substantially higher in infants 
compared with other age groups and there appeared to be a demographic shift in 
cases away from females and whites.
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objeCtives: To identify and understand hepatitis C virus (HCV) prevalence and 
mortality rates, disease course, and the availability of data on patient and viral 
characteristics that may affect treatment and outcomes. Methods: A targeted 
review was undertaken in MEDLINE, using a predefined search strategy, to identify 
studies describing HCV burden. Additional searches were performed on the ISPOR 
conference and key epidemiological websites. Results: A total of 1,773 references 
were identified. Results indicated that global HCV prevalence increased from 2.3% 
to 2.8% between 1990 and 2005, with highest prevalence in East Asia (> 3.5%). HCV 
screening programmes and mandatory reporting are present in only a few countries, 
so prevalence is likely to be even greater. In 2010, there were estimated to be 499,000 
deaths globally related to HCV, making HCV-related complications the 25th most 
common cause of death and a significant global health problem. The prevalence 
of HCV genotypes varies geographically. Genotype 1 is most prevalent in North 
and South America, Europe, and the Asia-Pacific region (~45%-80%). Genotype 3 is 
most prevalent in South Asia (Pakistan, India, and Thailand) (~52%-80%); genotype 
4 is most prevalent in the Middle East (~60%-92%). There is a lack of data for the 
majority of African and some Middle Eastern countries. Genotype 1 is associated 
with increased insulin resistance, worse response to therapy, and higher risk of 
developing cirrhosis and hepatocellular carcinoma. Genotype 3 is associated with 
increased steatosis (up to 73% of patients vs. 51% in patients with other genotypes) 
and fibrosis. ConClusions: In light of upcoming treatment alternatives, detailed 
epidemiological studies will help ascertain more accurately the prevalence of each 
HCV genotype, so that the true burden of HCV can be understood and treatments 
targeted appropriately.
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objeCtives: Varicella is a common and vaccine-preventable disease, but its impact 
on public health in Eastern Europe (EE) has received little attention. This study aimed 
to review the epidemiology and economic burden of varicella in EE. Methods: A 
systematic literature review was conducted in PubMed and government websites 
to identify published data on epidemiology and economic burden of varicella in EE. 
Extracted study data included varicella incidence, complications, mortality, vac-
cination program availability and coverage rates, as well as health care resource 
utilization and medical costs associated with varicella. Critical analyses of study 
quality and data gaps were analyzed at the country level. Results: Published 
varicella data were identified from fourteen countries including Bosnia Herzegovina, 
Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, 
Romania, Russia, Serbia, Slovakia, and Slovenia. Only Latvia has a universal vari-
cella vaccination program, while the remaining countries either only recommend 
8IFS, Interdisziplinaeres Facharztzentrum Sachsenhausen, Frankfurt/M, Germany, 9Center of 
Gastroenterology, Bonn, Germany, 10Center of Gastroenterology, Dortmund, Germany, 11Center 
of Gastroenterology, Herne, Germany, 12Factum – company for statistics, scientific information 
and communication mbH, Offenbach/Main, Germany, 13Roche Pharma AG, Grenzach-Wyhlen, 
Germany
objeCtives: Estimates assume that 400,000 to 500,000 people are chronically 
infected with Hepatitis C in Germany. About 27% of end-stage liver cirrhosis and 
25% of hepatocellular carcinoma are associated with HCV. The economic relevance 
of hepatitis C results from high costs for antiviral treatment as well as accom-
panying and secondary diseases. The aim of the study was to gain information 
on epidemiological characteristics, treatment outcomes and costs. Methods: 
Underlying data were collected in a non-interventional trial between 2008 and 
2011. Inclusion criteria were a confirmed HCV diagnosis and need for antivi-
ral treatment. Besides sociodemographic and clinical parameters, HCV related 
resource utilization was gathered for a subgroup of patients. Data presented are 
mean values. Results: Data on 7,637 patients receiving antiviral treatment with 
peginterferon-α -2a and ribavirin were collected. This analysis relates on 3,708 
patients without HIV coinfection and/or drug substitution treatment. Mean age 
was 43.7 years, 60.3% were male. Most patients had a genotype-1 (61.3%) or geno-
type-3 infection (28.5%). The majority of patients was treatment-naïve (86.5%), 
7.3% were relapser and 5.6% non-responder. Main sources of infection were injec-
tion drug use (34.8%) and blood products (14.2%). Mean duration of infection was 
13.6 years. In average 48.9% of treatment-naïve GT-1(4-6) and 63.0% of GT-2/3 
patients achieved SVR. For prior relapse patients and non-responder SVR-rates 
were: GT-1(4-6): 35.4%; GT-2/3: 58.5 and GT-1(4-6): 23.3% GT-2/3: 37.9%, respectively. 
Costs for antiviral treatment amount for € 20,889 in GT-1(4-6) patients and € 13,610 
in GT-2/3 patients. Costs for the management of adverse events or HCV-related 
diseases sum up for € 11.70. Ambulatory care, diagnostics procedures and hospi-
tal care amount for a small proportion of total costs. ConClusions: This study 
provides an overview on epidemiologic characteristics, treatment outcomes and 
treating costs in routine care. Treatment of HCV is costly and mainly affected by 
length of antiviral therapy.
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objeCtives: To estimate the number of cases of nosocomial skin and soft tissue 
infection (SSTIs) in adults caused by Gram-positive bacteria (GPB) in public hospi-
tals in Mexico. Methods: The total number of hospital discharges in patients ≥ 18 
years were extracted from databases of the National Health Information System. 
A rate of 5.97 cases of nosocomial infection (NI) per 100 discharges (issued by 
Instituto Mexicano del Seguro Social between 2011 and 2012) was applied. Through 
a systematic literature review and critical reading of studies developed under 
the Mexican setting (using the Critical Appraisal Skills Programme guidelines), 
we assessed the type of infection and determined the proportions of: microbio-
logical culture obtained and microbiological culture giving positive isolates. In 
the last stage, microorganisms were classified according to their Gram stain-
ing characteristics. Results: In the year 2011 there were 5,517,139 discharges 
from public hospital, inferring 329,373 cases of NI rate (16.9% under 18 years and 
83.1% in adults). We estimated that SSTIs represents 33.2% of NI (42,430 cases), of 
these, a microbiological culture was obtained only in 63.0% of the cases (26,731) 
and pathogen were isolated in 87.0% of microbiological cultures (23,256), among 
these, GPB was identified in 44.2%. According to our estimates a conservative 
number of cases of nosocomial SSTis in adults caused by GPB in 2011 was 10,279 
and the pathogens reported were Staphylococcus aureus (71.1%), Enterococcus spp 
(14.2%), and others (14.6%). ConClusions: Although we found high heterogeneity 
in NI reports which may decrease the quality of the estimates presented in this 
research, in our opinion these results could help clinicians in the choice of initial 
antibiotics in order to reduce the probability of failure due emergence of resist-
ant organisms.
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objeCtives: Chronic hepatitis C (CHC) treatment aims to prevent end-stage liver 
disease (ESLD) through sustained viral response (SVR). Treatment rates differ sig-
nificantly across Europe (< 1-16%). New protease-inhibitor based therapy offers an 
opportunity for increased SVR rates versus pegylated-interferon/ribavirin (> 70% 
vs. 50%). The analysis estimates the impact of various treatment rates on future 
ESLD sequelae associated with genotype-1 CHC in the UK. Methods: A Markov 
model was applied to estimate disease progression of a cohort of genotype-1 CHC 
patients over a 20-year time horizon. Endpoints included the following ESLD states: 
decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), liver transplan-
tation (LT) and liver-related death (LrD). Model structure, progression rates, CHC 
prevalence and disease severity at baseline were based on published economic 
evaluations. The number of ESLD cases averted by a 1-year increase in the current 
UK treatment rate (3%) to 12% and 16% was estimated for a 71.5% and 50.0% SVR 
rate. Results: Applying a 3% treatment rate and 71.5%/50.0% SVR rate predicted 
8590/8647 cumulative DCC and 3577/3595 HCC cases, 814/820 LTs and 7613/7659 
LrDs. The number of ESLD cases averted by applying a 12% treatment rate was 
estimated to be 565/395 DCC and 180/126 HCC cases, 51/36 LTs and 453/317 LrDs. 
